Company profile
Computational solutions for drug discovery
Cresset CADD Software, Torx DMTA and Discovery CRO solutions enable research chemists to make the molecules that matter, make better molecule design decisions, track compound synthesis with ease and get a unique perspective to advance their discovery project performance. By accessing CADD software, scientific expertise and enhanced efficiency by integrating in silico CADD and DMTA discovery solutions with first-class discovery research resources computational chemistry scientists will win the race to scientific success with seamless collaboration and insights across the Design-Make-Test-Analyze cycle.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CH01 | Transaction MzQ0NDg5OTA3OGFkaXF6a2N4
Published 26 Nov 2024 09:51
CH01 | Transaction MzQ0NDg5ODkyNmFkaXF6a2N4
Published 26 Nov 2024 09:50
CH01 | Transaction MzQ0NDY5MjEwN2FkaXF6a2N4
Published 25 Nov 2024 04:55
CS01 | Transaction MzQzOTMzNDEyMGFkaXF6a2N4
Published 14 Oct 2024 12:05
SH01 | Transaction MzQzMTgyOTgyNWFkaXF6a2N4
Published 12 Aug 2024 10:32
Company registered at Companies House
1 Sep 2018 to 30 Nov 2019
To develop a user friendly software for molecular simulations-driven computer-aided drug design.
1 Jul 2017 to 28 Feb 2018
Design of new molecules is a central task in the discovery of modern medicines. The properties of molecules and their biological responses are determined at the moment that a design is complete. Over the last 15 years a radical change in terms of the composition of Pharma R&D teams has occurred through increased usage of outsourcing (often in India, China...
1 Apr 2016 to 28 Feb 2017
The availability of crystallographic information for protein targets of pharmaceutical interest has dramatically increased in the recent years, even for those targets, such as trans-membrane receptors and ion channels, which until recently were considered extremely hard to crystallise. The availability and cost per calculation of high-performing computing...
1 Oct 2015 to 31 Dec 2015
The availability of crystallographic information for protein targets of pharmaceutical interest has dramatically increased in the recent years, even for those targets, such as Trans-membrane Receptors and Ion Channels, which until recently were considered extremely hard to crystallise. The availability and cost of high-performing computing through cloud-b...
1 May 2015 to 31 Oct 2015
Outsourcing of chemical synthesis is the backbone of the modern paradigm for pharmaceutical R&D, particularly in the early discovery phase of a project. This has meant a radical change in terms of the composition of Pharma R&D teams, where in the past there would have been a large team of chemists supporting each project, there is now one or two senior ch...
1 Aug 2012 to 31 Oct 2014
The E2D2 project will develop and demonstrate novel technologies combined in an integrated approach that identifies active medicinal drugs by exploiting Omics information. By developing technologies to link together the platforms of three UK SMEs, E2D2 will enable an information-led platform approach for drug discovery, delivering novel active drug compou...
1 Feb 2012 to 31 Aug 2013
To develop massively parallel software exploiting new many-core Graphics Processors (GPUs) to open up new application areas and markets for the computational drug discovery software.
1 Aug 2011 to 30 Sep 2012
The project aims to create a platform through which the partners are able to offer products and services to customers in the area of drug re-profiling or re-purposing. Re-profiling generally consists of looking for a new therapeutic application for an existing drug molecule, or stated another way, searching databases of known drug molecules to find compou...
